Glycan markers for fatty liver diseases

Publisher： John Wiley & Sons Inc

E-ISSN： 1440-1746|30|3|528-534

ISSN： 0815-9319

Source： JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, Vol.30, Iss.3, 2015-03, pp. : 528-534

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Treatment Strategies for Fatty Liver Diseases

By  

Reviews on Recent Clinical Trials, Vol. 9, Iss. 3, 2014-09 ,pp. : 185-194

Bentham Science Publishers

Access to resources Recommend Favorite

Letter: TNFα inhibitors and prevalence of fatty liver disease in chronic inflammatory diseases

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 42, Iss. 4, 2015-08 ,pp. : 489-489

John Wiley & Sons Inc

Access to resources Recommend Favorite

Markers of activated inflammatory cells correlate with severity of liver damage in children with nonalcoholic fatty liver disease

By                    

International Journal of Molecular Medicine, Vol. 30, Iss. 1, 2012-01 ,pp. : 49-56

Spandidos Publications

Access to resources Recommend Favorite

Biochemical markers, liver biopsy, or magnetic resonance elastography to detect or exclude advanced fibrosis in patients with nonalcoholic fatty liver disease

By  

HEPATOLOGY, Vol. 62, Iss. 1, 2015-07 ,pp. : 324-325

John Wiley & Sons Inc

Access to resources Recommend Favorite

Underappreciation of non‐alcoholic fatty liver disease by primary care clinicians: limited awareness of surrogate markers of fibrosis

By  

INTERNAL MEDICINE JOURNAL, Vol. 48, Iss. 2, 2018-02 ,pp. : 144-151

John Wiley & Sons Inc

Access to resources Recommend Favorite